Fern A I, Jay J L, Young H, MacKie R
Tennent Institute of Ophthalmology, Western Infirmary, Glasgow.
Br J Ophthalmol. 1992 Jun;76(6):332-5. doi: 10.1136/bjo.76.6.332.
Oral dapsone was used to treat five patients who presented in the acute inflammatory phase of ocular pemphigoid. The diagnosis was made clinically by identifying cicatricial changes which were in some cases difficult to find. In all cases it was the inflammatory rather than the cicatricial features which responded to treatment. An initial dose of 100 mg/day was effective without toxicity. When 150 mg/day was used patients experienced side effects. A clinical response was obtained after 1-4 weeks and could be maintained on a dose of between 50 mg on alternate days and 100 mg/day. Therapy was withdrawn during remissions which lasted up to 32 weeks but all cases required continuing therapy which has remained effective. Immunopathological examination was carried out on two occasions in all cases and although positive on at least one occasion the results did not correlate with disease activity or treatment. The inflammatory phase of ocular pemphigoid should be added to the list of diseases responsive to dapsone.
口服氨苯砜用于治疗5例处于瘢痕性类天疱疮急性炎症期的患者。临床诊断通过识别瘢痕性改变做出，在某些情况下这些改变难以发现。在所有病例中，对治疗有反应的是炎症而非瘢痕性特征。初始剂量为100毫克/天有效且无毒性。当使用150毫克/天的剂量时，患者出现了副作用。1至4周后获得了临床反应，维持剂量可在隔日50毫克至100毫克/天之间。在长达32周的缓解期期间停止治疗，但所有病例都需要持续治疗，且持续治疗一直有效。所有病例均进行了两次免疫病理检查，尽管至少有一次结果呈阳性，但结果与疾病活动或治疗无关。瘢痕性类天疱疮的炎症期应添加到对氨苯砜有反应的疾病列表中。
